Abiopharma

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation

CorMedix Inc. Announces Proposed Public Offering of Common Stock

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

IFF 发布《2024 Do More Good Report》彰显可持续发展与创新成果

IFF 2024年「Do More Good Report」、サステナビリティとイノベーションの進展を発表